The use of temozolomide in recurrent malignant gliomas

Cancer Treatment Reviews

Volumn 28, Issue 2, 2002, Pages 115-120

  Gaya, A ^a   Rees, J ^b   Greenstein, A ^c   Stebbing, J ^d  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c The Yorkshire Rotation   (United Kingdom)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Brain tumours; Chemotherapy; Glioblastoma multiforme; Gliomas; Temozolomide

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; DACARBAZINE; PROCARBAZINE; TEMOZOLOMIDE;

ARTICLE; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; BRAIN SURGERY; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG COST; DRUG EXCRETION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; GLIOBLASTOMA; HUMAN; LICENSING; MALIGNANT NEOPLASTIC DISEASE; NAUSEA AND VOMITING; PATIENT CARE; POSTOPERATIVE PERIOD; QUALITY OF LIFE; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0036553213     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2002.0261     Document Type: Article

References (38)

1. Incidence of brain tumours in two English counties: A population based study
2. Descriptive epidemiology of primary brain and CNS tumours: Results from the central brain tumour registry of the United States, 1990-1994
3. Neoplasms of the central nervous system
4. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A co-operative clinical trial
5. Randomised comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery
6. Randomised trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high grade astrocytoma: An MRC trial
7. Cancer statistics, 1999
8. CSF levels of temozolomide as a surrogate marker for brain penetration
9. DNA mismatch repair and O6 alkylguanine DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma
10. Multicenter phase ii trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
11. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma
12. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse
13. Multicentre phase II trial of temozolomide in patients with GBM at first relapse
14. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide
15. A phase II study of extended low dose temozolomide in recurrent malignant gliomas
16. Phase II study of temozolomide in patients with relapsing high-grade gliomas and poor performance status
17. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high grade glioma
18. Temozolomide as a second line systemic regimen in recurrent high grade glioma: A phase II study
19. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours
20. Phase I study of temozolomide in paediatric patients with advanced cancer
21. Response criteria for phase Il studies of supratentorial malignant glioma
22. Randomised trial of temozolomide vs procarbazine in glioblastoma multiforme at first relapse
23. Re-evaluation of procarbazine for the treatment of recurrent malignant CNS tumours
24. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent GBM
25. Pre-radiation treatment of newly diagnosed anaplastic astrocytomas and glioblastoma multiforme using temozolomide
26. New approaches for temozolomide therapy: Use in newly diagnosed gliomas
27. Promising survival with concomitant and adjuvant temozolomide for newly diagnosed GBM
28. Promising survival for patients with newly diagnosed GBM treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide
29. Irinotecan therapy in adults with recurrent or progressive malignant glioma
30. Temozolomide in combination with other cytotoxic agents
31. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy
32. Understanding low grade glioma: A decade of progress
33. A phase II trial of temozolomide for patients with recurren or progressive brain metastases
34. Current and future developments in the use of temozolomide for the treatment of brain tumours
35. Phase II study of temozolomide in the treatment of anaplastic astrocytoma at first relapse
36. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor marimastat in recurrent and progresive GBM